JP2021534108A5 - - Google Patents

Info

Publication number
JP2021534108A5
JP2021534108A5 JP2021506683A JP2021506683A JP2021534108A5 JP 2021534108 A5 JP2021534108 A5 JP 2021534108A5 JP 2021506683 A JP2021506683 A JP 2021506683A JP 2021506683 A JP2021506683 A JP 2021506683A JP 2021534108 A5 JP2021534108 A5 JP 2021534108A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
independently selected
heterocyclyls
pharmaceutically acceptable
Prior art date
Application number
JP2021506683A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020033520A5 (https=
JP2021534108A (ja
JP7651451B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/045466 external-priority patent/WO2020033520A1/en
Publication of JP2021534108A publication Critical patent/JP2021534108A/ja
Publication of JP2021534108A5 publication Critical patent/JP2021534108A5/ja
Publication of JPWO2020033520A5 publication Critical patent/JPWO2020033520A5/ja
Application granted granted Critical
Publication of JP7651451B2 publication Critical patent/JP7651451B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021506683A 2018-08-08 2019-08-07 Pad酵素のインドールおよびアザインドール阻害剤 Active JP7651451B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862715850P 2018-08-08 2018-08-08
US62/715,850 2018-08-08
PCT/US2019/045466 WO2020033520A1 (en) 2018-08-08 2019-08-07 Indole and azaindole inhibitors of pad enzymes

Publications (4)

Publication Number Publication Date
JP2021534108A JP2021534108A (ja) 2021-12-09
JP2021534108A5 true JP2021534108A5 (https=) 2022-08-16
JPWO2020033520A5 JPWO2020033520A5 (https=) 2022-08-16
JP7651451B2 JP7651451B2 (ja) 2025-03-26

Family

ID=67766306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021506683A Active JP7651451B2 (ja) 2018-08-08 2019-08-07 Pad酵素のインドールおよびアザインドール阻害剤

Country Status (18)

Country Link
US (1) US11524959B1 (https=)
EP (1) EP3833440A1 (https=)
JP (1) JP7651451B2 (https=)
KR (1) KR102885181B1 (https=)
CN (1) CN112805067B (https=)
AR (1) AR115920A1 (https=)
AU (1) AU2019319835A1 (https=)
BR (1) BR112021002091A2 (https=)
CA (1) CA3108791A1 (https=)
CL (1) CL2021000296A1 (https=)
CO (1) CO2021001217A2 (https=)
EA (1) EA202190462A1 (https=)
IL (1) IL280650A (https=)
MX (1) MX2021001565A (https=)
PE (1) PE20211068A1 (https=)
SG (1) SG11202101174RA (https=)
TW (1) TW202019415A (https=)
WO (1) WO2020033520A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3833671B1 (en) 2018-08-08 2022-08-24 Bristol-Myers Squibb Company Substituted thienopyrroles as pad4 inhibitors
AU2019319835A1 (en) 2018-08-08 2021-03-25 Bristol-Myers Squibb Company Indole and azaindole inhibitors of PAD enzymes
EP4100405A1 (en) 2020-02-06 2022-12-14 Bristol-Myers Squibb Company Macrocyclic pad4 inhibitors useful as immunosuppressant
TW202140477A (zh) 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環pad4抑制劑
EP4143189A1 (en) * 2020-04-30 2023-03-08 Gilead Sciences, Inc. Macrocyclic inhibitors of peptidylarginine deiminases
CN111943947B (zh) * 2020-07-24 2021-04-30 重庆文理学院 1H-吡咯[2,3-b]吡啶衍生物及其合成方法与应用
CN116075510A (zh) 2020-08-19 2023-05-05 百时美施贵宝公司 1H-苯并[d]咪唑衍生物作为TLR9抑制剂用于治疗纤维化
WO2022040267A1 (en) 2020-08-19 2022-02-24 Bristol-Myers Squibb Company 1h-pyrrolo[3,2-c]pyridine and 1h-pyrrolo[2,3-c]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis
TW202241884A (zh) * 2020-12-22 2022-11-01 美商基利科學股份有限公司 肽基精胺酸去亞胺酶之抑制劑
WO2022140428A2 (en) * 2020-12-22 2022-06-30 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
WO2025024265A1 (en) 2023-07-21 2025-01-30 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad4 modulators
CN117427074A (zh) * 2023-11-13 2024-01-23 山东第一医科大学(山东省医学科学院) 四氢喹啉醇作为铁死亡抑制剂在制备急性肾损伤药物中的应用
WO2026020127A2 (en) 2024-07-19 2026-01-22 Bristol-Myers Squibb Company Methods of assessing citrullination and activity of pad2 modulators

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55684B1 (sr) 2012-07-26 2017-07-31 Glaxo Group Ltd 2-(azaindol-2-il)benzimidazoli kao pad4 inhibitori
US10407407B2 (en) 2015-05-21 2019-09-10 Glaxosmithkline Intellectual Property Development Limited Benzoimidazole derivatives as PAD4 inhibitors
AR107030A1 (es) 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores aza-bencimidazol de pad4
AR107032A1 (es) 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
RU2747431C2 (ru) 2015-12-22 2021-05-05 Кансера Аб Бициклические гидроксамовые кислоты, полезные в качестве ингибиторов активности деацетилазы гистонов млекопитающих
JP6926126B2 (ja) 2016-02-23 2021-08-25 パドロック・セラピューティクス・インコーポレイテッドPadlock Therapeutics, Inc. Pad4のヘテロアリール阻害剤
KR102398941B1 (ko) 2016-07-27 2022-05-17 패들락 테라퓨틱스, 인코포레이티드 Pad4의 공유결합성 억제제
JP7118951B2 (ja) 2016-09-12 2022-08-16 パドロック・セラピューティクス・インコーポレイテッド Pad4のヘテロアリール阻害剤
CN110582489B (zh) 2017-06-30 2023-10-27 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
CN112789087B (zh) 2018-08-08 2024-08-13 百时美施贵宝公司 Pad酶的苯并咪唑抑制剂
AU2019319835A1 (en) 2018-08-08 2021-03-25 Bristol-Myers Squibb Company Indole and azaindole inhibitors of PAD enzymes
WO2020033488A1 (en) 2018-08-08 2020-02-13 Bristol-Myers Squibb Company Substituted benzimidazoles as pad4 inhibitors
EP3833671B1 (en) 2018-08-08 2022-08-24 Bristol-Myers Squibb Company Substituted thienopyrroles as pad4 inhibitors

Similar Documents

Publication Publication Date Title
JP2021534108A5 (https=)
JP2021534106A5 (https=)
JP2021534097A5 (https=)
JP2021515010A5 (https=)
JP2021534104A5 (https=)
JPWO2023099592A5 (https=)
JP2008535903A5 (https=)
JP2020505376A5 (https=)
JP2017526675A5 (https=)
JP2012519691A5 (https=)
JP2016503797A5 (https=)
JP2013538230A5 (https=)
JP2017537940A5 (https=)
JP2009504764A5 (https=)
JP2015529235A5 (https=)
RU2015122757A (ru) Бициклические соединения мочевины, тиомочевины, гуанидина и цианогуанидина, пригодные для лечения боли
RU2008152763A (ru) Применение агонистов каннабиноидного рецептора в качестве индуцирующих гипотермию лекарственных средств для лечения ишемии
RU2005107314A (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью
JP2009535307A5 (https=)
JP2016534134A5 (https=)
JP2014531434A5 (https=)
JP2012517444A5 (https=)
RU2018127728A (ru) Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич
JP2008526999A5 (https=)
JP2014508804A5 (https=)